dc.contributor.author | Ross-Adams, H | en_US |
dc.contributor.author | Ball, S | en_US |
dc.contributor.author | Lawrenson, K | en_US |
dc.contributor.author | Halim, S | en_US |
dc.contributor.author | Russell, R | en_US |
dc.contributor.author | Wells, C | en_US |
dc.contributor.author | Strand, SH | en_US |
dc.contributor.author | Orntoft, TF | en_US |
dc.contributor.author | Larson, M | en_US |
dc.contributor.author | Armasu, S | en_US |
dc.contributor.author | Massie, CE | en_US |
dc.contributor.author | Asim, M | en_US |
dc.contributor.author | Mortensen, MM | en_US |
dc.contributor.author | Borre, M | en_US |
dc.contributor.author | Woodfine, K | en_US |
dc.contributor.author | Warren, AY | en_US |
dc.contributor.author | Lamb, AD | en_US |
dc.contributor.author | Kay, J | en_US |
dc.contributor.author | Whitaker, H | en_US |
dc.contributor.author | Ramos-Montoya, A | en_US |
dc.contributor.author | Murrell, A | en_US |
dc.contributor.author | Sorensen, KD | en_US |
dc.contributor.author | Fridley, BL | en_US |
dc.contributor.author | Goode, EL | en_US |
dc.contributor.author | Gayther, SA | en_US |
dc.contributor.author | Masters, J | en_US |
dc.contributor.author | Neal, DE | en_US |
dc.contributor.author | Mills, IG | en_US |
dc.date.accessioned | 2018-02-23T14:49:02Z | |
dc.date.available | 2016-09-26 | en_US |
dc.date.issued | 2016-11-15 | en_US |
dc.date.submitted | 2018-02-20T11:21:33.594Z | |
dc.identifier.other | 10.18632/oncotarget | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/33483 | |
dc.description.sponsorship | We acknowledge the support of the National Cancer
Research Prostate Cancer: Mechanisms of Progression
and Treatment (ProMPT) collaborative (grant code
G0500966/75466), which has funded tissue and urine
collections in Cambridge, as well as the Human Research
Tissue bank, which is supported by the NIHR Cambridge
Biomedical Research Centre. We acknowledge the support
of The University of Cambridge, Cancer Research UK
and Hutchison Whampoa Limited, and the support of
Cancer Research UK Cambridge Institute Genomics
and Bioinformatics core facilities. We thank Dr Thorunn
Rafnar for helpful discussions and critical review of the
manuscript, and Dr Gerhart Ryffel for his kind gift of
the HNF1B plasmid. This work was funded by a CRUK
program grant awarded to DEN. HR-A and SB were
supported by EU Framework Programme 7 grant 202059
(ProMark; http://www.promark-fp7.eu/). The Aarhus
Prostate Cancer study is supported by the Danish Strategic
Research Council and The Danish Cancer Society. This
work was in part supported by the NIH grants R01
CA122443 and P30-CA13083 to ELG and P50-CA136393
to Mayo Clinic SPORE Ovarian Cancer, to ELG. I.G.M.
is an Associate Professor at Queen’s University Belfast
and funded through the PCUK/Movember Centre of
Excellence for Prostate Cancer Research | en_US |
dc.format.extent | 74734 - 74746 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | ONCOTARGET | en_US |
dc.rights | Creative Commons Attribution License | |
dc.subject | HNF1B | en_US |
dc.subject | eQTL | en_US |
dc.subject | prostate | en_US |
dc.subject | ovarian | en_US |
dc.subject | cancer | en_US |
dc.title | HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer | en_US |
dc.type | Article | |
dc.rights.holder | 2017. The authors | |
dc.identifier.doi | 10.18632/oncotarget.12543 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000389632800025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 46 | en_US |
pubs.notes | No embargo | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 7 | en_US |